These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 8931636

  • 21. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Watanabe Y, Yamashita K.
    Metabolism; 1992 Apr; 41(4):359-63. PubMed ID: 1556941
    [Abstract] [Full Text] [Related]

  • 22. Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas.
    Schmid R, Schusdziarra V, Aulehner R, Weigert N, Classen M.
    Z Gastroenterol; 1990 Jun; 28(6):280-4. PubMed ID: 2238756
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets.
    Siegel EG, Schulze A, Schmidt WE, Creutzfeldt W.
    Eur J Clin Invest; 1992 Mar; 22(3):154-7. PubMed ID: 1582439
    [Abstract] [Full Text] [Related]

  • 24. Effect of GIP and GLP-1 antagonists on insulin release in the rat.
    Tseng CC, Zhang XY, Wolfe MM.
    Am J Physiol; 1999 Jun; 276(6):E1049-54. PubMed ID: 10362617
    [Abstract] [Full Text] [Related]

  • 25. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.
    Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, Demuth HU.
    J Biol Chem; 1996 Sep 20; 271(38):23222-9. PubMed ID: 8798518
    [Abstract] [Full Text] [Related]

  • 26. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V, Vasu S, Flatt PR, Irwin N.
    Diabetes Obes Metab; 2014 Apr 20; 16(4):357-65. PubMed ID: 24164718
    [Abstract] [Full Text] [Related]

  • 27. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
    Dirksen C, Bojsen-Møller KN, Jørgensen NB, Jacobsen SH, Kristiansen VB, Naver LS, Hansen DL, Worm D, Holst JJ, Madsbad S.
    Diabetologia; 2013 Dec 20; 56(12):2679-87. PubMed ID: 24048673
    [Abstract] [Full Text] [Related]

  • 28. Effect of glucagon-like peptide-1 on insulin secretion.
    Shima K, Hirota M, Ohboshi C.
    Regul Pept; 1988 Aug 20; 22(3):245-52. PubMed ID: 3051138
    [Abstract] [Full Text] [Related]

  • 29. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD, Gault VA, O'Harte FP, Flatt PR.
    Diabetes Obes Metab; 2005 Sep 20; 7(5):595-604. PubMed ID: 16050953
    [Abstract] [Full Text] [Related]

  • 30. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.
    Diabetes; 2004 Mar 20; 53(3):654-62. PubMed ID: 14988249
    [Abstract] [Full Text] [Related]

  • 31. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
    Hinke SA, Manhart S, Kühn-Wache K, Nian C, Demuth HU, Pederson RA, McIntosh CH.
    J Biol Chem; 2004 Feb 06; 279(6):3998-4006. PubMed ID: 14610075
    [Abstract] [Full Text] [Related]

  • 32. Novel extrapancreatic effects of incretin.
    Yamada Y, Tsukiyama K, Sato T, Shimizu T, Fujita H, Narita T.
    J Diabetes Investig; 2016 Apr 06; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [Abstract] [Full Text] [Related]

  • 33. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
    van der Burg MP, Guicherit OR, Frölich M, Gooszen HG.
    Regul Pept; 1995 Dec 07; 60(1):61-7. PubMed ID: 8747785
    [Abstract] [Full Text] [Related]

  • 34. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ.
    Diabetologia; 1998 Mar 07; 41(3):271-8. PubMed ID: 9541166
    [Abstract] [Full Text] [Related]

  • 35. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas.
    Fehmann HC, Göke B, Göke R, Trautmann ME, Arnold R.
    FEBS Lett; 1989 Jul 31; 252(1-2):109-12. PubMed ID: 2668027
    [Abstract] [Full Text] [Related]

  • 36. The ageing entero-insular axis.
    Ranganath L, Sedgwick I, Morgan L, Wright J, Marks V.
    Diabetologia; 1998 Nov 31; 41(11):1309-13. PubMed ID: 9833938
    [Abstract] [Full Text] [Related]

  • 37. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
    Svane MS, Bojsen-Møller KN, Nielsen S, Jørgensen NB, Dirksen C, Bendtsen F, Kristiansen VB, Hartmann B, Holst JJ, Madsbad S.
    Am J Physiol Endocrinol Metab; 2016 Apr 01; 310(7):E505-14. PubMed ID: 26786780
    [Abstract] [Full Text] [Related]

  • 38. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
    Roberge JN, Brubaker PL.
    Endocrinology; 1993 Jul 01; 133(1):233-40. PubMed ID: 8319572
    [Abstract] [Full Text] [Related]

  • 39. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ, Berg S, Kohnert KD, Heinke P, Salzsieder E.
    Biol Chem; 2011 Mar 01; 392(3):209-15. PubMed ID: 21281062
    [Abstract] [Full Text] [Related]

  • 40. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA, Kerr BD, Harriott P, Flatt PR.
    Clin Sci (Lond); 2011 Aug 01; 121(3):107-17. PubMed ID: 21332446
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.